Cupertino, CA, United States of America

Huang-Tsu Chen

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Taipei, TW (2022)
  • Cupertino, CA (US) (2018 - 2024)

Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations of Huang-Tsu Chen

Introduction

Huang-Tsu Chen is a notable inventor based in Cupertino, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of anti-angiogenesis fusion proteins. With a total of 6 patents, his work is recognized for its potential therapeutic applications in treating diseases associated with angiogenesis.

Latest Patents

One of Huang-Tsu Chen's latest patents is titled "Anti-angiogenesis fusion protein and uses thereof." This invention provides a bi-functional fusion protein, represented as (AT)a-Fc-(VT)b, which simultaneously targets vascular endothelial growth factor (VEGF) and angiopoietins (ANGs). In this formula, AT serves as an ANG binding motif, while VT acts as a VEGF binding motif. The fragment crystallizable region (Fc) is derived from the N-terminal of Immunoglobulin G (IgG). Each of the integers a and b ranges from 1 to 10. The bi-functional fusion proteins consist of two or more domains of human proteins and are composed entirely of human sequences. This design is expected to be non-immunogenic and has the potential for therapeutic use in targeting diseases associated with angiogenesis.

Career Highlights

Huang-Tsu Chen has worked with several companies throughout his career, including Ap Biosciences Inc. and Trican Biotechnology Co., Ltd. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.

Collaborations

Some of his notable coworkers include Jiun-Shyang Leou and Jeng-Horng Her. Their collaborative efforts have likely played a role in advancing the research and development of innovative biotechnological solutions.

Conclusion

Huang-Tsu Chen's contributions to the field of biotechnology, particularly through his patents on anti-angiogenesis fusion proteins, highlight his innovative spirit and dedication to addressing critical health challenges. His work continues to pave the way for potential therapeutic advancements in treating angiogenesis-associated diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…